GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference
Topics/Oncology/ACS 2026 Statastical Report
102

ACS 2026 Statastical Report

Clinical knowledge base written and curated by GastroAGI Team from primary medical literatureLast updated January 1, 2026

The ACS  publishes an annual "Cancer Facts & Figures" report, which provides comprehensive statistics on cancer incidence, survival rates, mortality, and trends in the United States. The report typically highlights progress in early detection, advancements in treatment, and disparities in cancer outcomes. For example, recent statistics have shown that the 5-year cancer survival rate has reached 70%, a significant milestone reflecting decades of improvement in cancer research, early screening, and innovative therapies such as immunotherapy and targeted treatments.

However, underlying challenges persist, including disparities in access to care, variations in survival rates by cancer type, and missed opportunities for early detection. The ACS continues to emphasize the need for equitable and personalized approaches to cancer prevention, treatment, and survivorship care.

Related Q&A

103

GEP-NET- Gastroenterology Jan.26

Overview of GEP-NETs Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a subtype of neuroendocrine neoplasms (NENs) that arise from neuroendocrine cells within the gastrointestinal (GI) tract and pancreas. These tumors...

104

T1 CRC and ESD(GIE, Jan-2026)

T1 Colorectal Cancer (CRC) T1 CRC refers to early-stage colorectal cancer where the tumor has invaded the submucosa but has not yet spread further. It is subdivided into...

105

Novel Therapeutic approach for pancreatic cancer(GIE,Jan-2026)

The novel therapeutic approach for pancreatic cancer, as detailed in the study published in Gastrointestinal Endoscopy (GIE), January 2026, involves the combination of intratumoral phosphorus-32 (32P) implantation with...

106

Screening for Esophageal Cancer

Screening for esophageal cancer is a critical strategy to improve early detection and survival rates, given the disease's poor prognosis due to late-stage diagnosis. However, effective screening approaches...

107

Glecirasib with or without Cetuximab in previously treated CRC with KRAS mutation - Lancet Gastroenterol Hepatol

The study published in Lancet Gastroenterology & Hepatology investigates the efficacy and safety of glecirasib (JAB-21822), a novel covalent small molecule KRASG12C inhibitor, as monotherapy or in combination...

108

New Drugs for hepatobiliary Cancers - J of Hepatology - Jan.26

The treatment of hepatobiliary cancers, including hepatocellular carcinoma (HCC) and biliary tract cancer (BTC), is undergoing significant advancements with the development of novel drugs and therapeutic strategies. These...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer